Boyiadzis M, Wei AH, Paiva B, Freeman SD, Kaspers G, Chyla B, Hersey S, Patel R, Maloney B, Zumofen MB, Van Hoef M, Wulff B, Obourn V, Patel S, de Menezes DL, Shi Q, Bengoudifa B, Dimier N, Prior TJ, Roboz GJ, Prebet T. Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium. Cancer. 2025;131(13):10.1002/cncr.35960
Lawrence EM, Cooray A, Kueh AJ, Pal M, Tai L, Garnham AL, Li-Wai-Suen CSN, Vanyai H, Gouil Q, Lancaster J, Callegari S, Whelan L, Lieschke E, Thomas A, Strasser A, Liao Y, Shi W, Wei AH, Herold MJ. Transcriptomic changes including p53 dysregulation prime DNMT3A mutant cells for transformation. EMBO Reports. 2025;26(11):10.1038/s44319-025-00450-4
Wang ES, Cortes JE, Wei AH, De Botton S, Curti A, Montesinos P, Yee KWL, Jurcic JG, Donnellan WB, Yang J, Jonas BA, Sheppard A, Tian H, Watts JM. A phase 2 study of olutasidenib in relapsed/refractory acute myeloid leukemia: Outcomes by number of prior treatment regimens.Journal of Clinical Oncology. 2025;43(16_suppl):10.1200/jco.2025.43.16_suppl.6545
Shaw B, Ling VY, Hubbard RE, Bajel A, Hiwase D, Marlton P, Patil S, Perera T, Perram J, Tan SY, Tan XN, Wei A, Hamad N, Chua CC. Frailty and geriatric assessments in older patients diagnosed with acute myeloid leukaemia: an Australasian Leukaemia and Lymphoma Group consensus statement. Internal Medicine Journal. 2025;55(6):10.1111/imj.70086
Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Oshima MU, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly LS, Kim H-J, Stelljes M, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Chen C, Hasabou N, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Mendizabal A, Devine SM, Horowitz MM, Chen Y-B. Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD–mutated AML. Blood. 2025;145(19):10.1182/blood.2024025154
Chua CC, Loo S, Fong CY, Ting SB, Tiong IS, Fleming S, Anstee NS, Ivey A, Ashby M, Teh T-C, Reynolds J, Roberts AW, Wei AH. Final analysis of the phase 1b Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT). Blood Advances. 2025;9(8):10.1182/bloodadvances.2024014900
Peng H, Jabbari JS, Tian L, Wang C, You Y, Chua CC, Anstee NS, Amin N, Wei AH, Davidson N, Roberts AW, Huang D, Ritchie ME, Thijssen R. Single-cell Rapid Capture Hybridization sequencing to reliably detect isoform usage and coding mutations in targeted genes. Genome Research. 2025;35(4):10.1101/gr.279322.124
Gong J-N, Djajawi TM, Moujalled DM, Pomilio G, Khong T, Zhang L-P, Fedele PL, Low MS, Anderson MA, Riffkin CD, White CA, Lan P, Lessene G, Herold MJ, Strasser A, Spencer A, Grigoriadis G, Wei AH, van Delft MF, Roberts AW, Huang DCS. Re-appraising assays on permeabilized blood cancer cells testing venetoclax or other BH3 mimetic agents selectively targeting pro-survival BCL2 proteins. Cell Death & Differentiation. 2025;:10.1038/s41418-025-01487-7
De Botton S, Récher C, Cortes J, Curti A, Fenaux P, Peterlin P, Pigneux A, Yee K, Wei A, Mims A, Schiller G, Chao MM, Tian H, Watts JM. Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm. British Journal of Haematology. 2025;206(4):10.1111/bjh.19944
Pullarkat V, Pratz KW, Döhner H, Recher C, Thirman MJ, DiNardo CD, Fenaux P, Schuh AC, Wei AH, Pigneux A, Jang J-H, Juliusson G, Miyazaki Y, Selleslag D, Arellano ML, Liu C, Ridgeway JA, Potluri J, Schuler J, Konopleva M. Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia. Blood Cancer Journal. 2025;15(1):10.1038/s41408-025-01263-3
